Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection.

Journal: Transplantation direct
Published Date: Nov 3, 2017

Abstract

Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant recipients (RTRs), a patient population on lifelong immunosuppression. Here, we describe 3 RTRs who received 8 weeks of LDV/SOF, meeting the standard criteria for shortened treatment duration. All 3 patients tolerated treatment well and achieved sustained virologic response at 12 weeks (SVR 12).

Authors

  • Jennifer S Husson
    The Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD.
  • Bharath Ravichandran
    Department of Pharmacy, University of Maryland, Baltimore, MD.
  • Srijana Jonchhe
    Department of Pharmacy, University of Maryland, Baltimore, MD.
  • Shyamasundaran Kottilil
    The Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD.
  • Eleanor Wilson
    The Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals